Epidemiologial Studies of β-Carotene and Lung Cancer

Study

Willett et al, 1984 Nomura et al, 1985 Menkes et al, 1986 Gey et al, 1987 Wald et al, 1988 Kune et al, 1989 Connett et al, 1989 Knekt et al, 1990 Stäheline et al, 1991 ATBC Trial, 1994

Parameter Measured Outcome

ATBC Trial





Intervention Trials: β -Carotene and Lung Cancer¹

Study **ATBC (ATBC Cancer Prevention Group**, 1994)

Study Population 29.133 men 50-69 yr. **Duration: 6 vr**

Daily Dose 20 mg β -carotene and/or 50 mg vitamin E

Results 18% 🛧 lung cancer in smokers

CARET (Omenn et al, 1996)

asbestos workers, 45-69 vr **Duration: 4 yr**

18,254 smokers and **30 mg** β -carotene and 25,000 IU retinol


25% 🔶 lung cancer

PHS (Hennekens et al., 1996)

22,071 male physicians, 40-48 yr **Duration: 12 yr** **50 mg** β -carotene (alternate days)

NS effects on cancer, including smokers


¹ primary Prevention Randomized, Double-Blind, Placebo-Controlled






Average Serum Levels of β-Carotene in Intervention Trials

| Study | | μ g/dl |
|--------|-----------------------------|---------------|
| ATBC | | 300 |
| CARET | | 210 |
| PHS | | 120 |
| NHANES | 5 th percentile | 5 |
| | 95 th percentile | 50 |












Comparison of Lung β–Carotene and Retinol Levels in Man and Ferret ^{1,2}


| | Control | Smoke + β-Carotene |
|------------|-----------------|-----------------------|
| | nmol/g tissue | |
| β-Carotene | | |
| Human | 0.24 ± 0.50 | 0.76 (n=2) |
| Ferret | 0.10 ± 0.08 | 1.71 ± 0.22 |
| | | |
| Retinol | | |
| Human | 0.52 ± 0.21 | 0.56 (n=2) |
| Ferret | 0.41 ± 0.07 | 0.38 ± 0.05 |
| | | |


1)Redich et al., Cancer Epidemiol Biomarkers Prev 1998;7:211-4. 2)Wang et al., J Natl Cancer Inst 1999;91:60-6.


























Concentrations of carotene and retinoids in four groups of ferrets after six months of treatment

| | Control | Smoke Exposed | | Smoke-exposed & β-C supplemented |
|---------------|---------|------------------|------|-------------------------------------|
| Lung Tissue | | (pmol/100 mg) | | |
| β-Carotene | 9 | Trace | 2618 | 171 |
| Retinol | 41 | 37 | 44 | 38 |
| Retinoic acid | 1.7 | ND* | 0.4 | ND* |


(ND* = not detectable)

















RA Destruction by CYP 450 Enzymes

1) Gradelet et al. 1996

2) Paolini et al. 1999


Robert M. Russell, M.D., Director Human Nutrition Research Center on Aging at Tufts University









Human Nutrition Research Center on Aging at Tufts University



















Mechanism


P450 enzymes

Retinoic Acid

↑ c-Fos, c-Jun

FARβ

↑ Cell proliferation





Oxidized Products Facilitate Carcinogenesis

Salgo et al. 1999

Perocco et al. 1999


Prakash et al β- Apo 10' and 14' (not β-Carotene) can facilitate DNA binding of benzo[a]pyrene metabolites



Oxidized Products

1) Induce P450 enzymes

2) Binding of smoke derived carcinogens to DNA





Strategy


Limit amount of β-Carotene metabolites formed





Ferret Study Design












1. Dose counts

2. Mechanisms

3. Importance of animal studies

4. Genomics





Future Research Needs

- 1) Animal Models (dose response)
- 2) Metabolism, breakdown; and biologic activity
- 3) Genomics

